Systemic sclerosis: Advances towards stratified medicine

Area of Science:

• Rheumatology and Immunology
• Translational Medicine
• Biomarker Discovery

Background:

• Systemic sclerosis (SSc) patient outcomes, including mortality and disease progression, are influenced by demographic, clinical, and serological factors.
• Predicting individual SSc disease trajectory is crucial for stratified management but remains a significant challenge.

Purpose of the Study:

• To explore the potential of recent technological advancements in subgrouping SSc patients for risk stratification.
• To identify non-invasive biomarkers for predicting organ involvement, disease activity, and treatment response in SSc.
• To enhance clinical trial design and facilitate the identification of targeted therapies for SSc.

Main Methods:

• Systematic analysis of high-dimensional clinical data integrated with genetic, transcriptomic, and proteomic information.
• Exploration of novel non-invasive biomarkers for disease assessment.
• Standardization of outcome measures in patient selection for clinical trials.

Main Results:

• Technological advances offer new possibilities for SSc patient subgrouping based on risk stratification.
• High-dimensional data analysis combined with molecular information can identify predictive factors for SSc outcomes.
• Identification of non-invasive biomarkers holds promise for monitoring disease activity and therapeutic response.

Conclusions:

• Advanced data analysis and biomarker research can lead to a more personalized approach to SSc management.
• Improved patient stratification and outcome standardization are key to advancing SSc clinical trial design.
• Targeted therapies informed by molecular signatures and clinical phenotypes are expected to improve SSc treatment efficacy.